Skip to content
2000
Volume 21, Issue 1
  • ISSN: 2772-4344
  • E-ISSN: 2772-4352

Abstract

Introduction

The coronavirus disease 2019 (COVID-19) pandemic, caused the by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound impact on public health, overburdening healthcare systems, and disrupting global economies. Moreover, the absence of specific antiviral drugs remains a major challenge in COVID-19 treatment. The SARS-CoV-2 main protease (Mpro) is a crucial therapeutic target due to its essential role in viral replication. The objective of this study was to identify natural compounds with potential inhibitory activity against SARS-CoV-2 Mpro, which could be used alone or in combination with repositioned drugs for the treatment of COVID-19.

Methods

A total of 224,205 natural compounds from the ZINC database were virtually screened against SARS-CoV-2 Mpro using a sequential molecular docking protocol with increasing levels of exhaustiveness. The top 88 compounds were further evaluated using MM-GBSA calculations to determine their binding free energies. Molecular dynamics (MD) simulations (100 ns) were conducted for the top four compounds to assess complex stability and ligand interactions. Structural stability and protein-ligand interactions were assessed using various statistical parameters. Post-MD binding free energy calculations were also performed.

Results

Four compounds, ZINC000085626103, ZINC000085625768, ZINC000085488571, and ZINC000085569275, were identified based on their docking scores (ranging from -11.876 to -12.682 kcal/mol) and MM-GBSA binding energies (ranging from -50.11 to -64.8 kcal/mol). All these compounds formed stable complexes with Mpro during MD simulations, with ZINC000085488571 exhibiting the lowest protein RMSD (0.15 ± 0.02 nm) and RMSF (0.10 ± 0.04 nm). These compounds interacted with key active site residues and maintained stable hydrogen bonding and compact structures throughout the simulation. Post-simulation binding free energy values ranged from -38.29 to -18.07 kcal/mol, further indicating strong and stable binding affinities.

Discussion

The screening results confirmed the strong binding affinity and structural stability of the selected natural compounds at the SARS-CoV-2 Mpro active site. The MD simulation results further highlighted consistent engagement with catalytically relevant residues, indicating their potential for inhibitory activity.

Conclusion

This study identifies four natural compounds with strong binding affinity and structural stability against SARS-CoV-2 Mpro, supporting their candidacy for further investigation as potential antiviral agents for COVID-19 treatment.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raaidd/10.2174/0127724344379865250709163918
2025-07-17
2026-03-02

  • From This Site

    /content/journals/raaidd/10.2174/0127724344379865250709163918
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KumariM. LuR.M. LiM.C. A critical overview of current progress for COVID-19: Development of vaccines, antiviral drugs, and therapeutic antibodies.J. Biomed. Sci.20222916810.1186/s12929‑022‑00852‑9 36096815
     [Google Scholar]
  2. SheahanT.P. FriemanM.B. The continued epidemic threat of SARS-CoV-2 and implications for the future of global public health.Curr. Opin. Virol.202040374010.1016/j.coviro.2020.05.010 32569751
     [Google Scholar]
  3. RiederA.S. DenizB.F. NettoC.A. WyseA.T.S. A review of in silico research, SARS-CoV-2, and neurodegeneration: Focus on papain-Like protease.Neurotox. Res.20224051553156910.1007/s12640‑022‑00542‑2 35917086
     [Google Scholar]
  4. VitielloA. FerraraF. AutiA.M. Di DomenicoM. BoccellinoM. Advances in the Omicron variant development.J. Intern. Med.20222921819010.1111/joim.13478 35289434
     [Google Scholar]
  5. SuahJ.L. TngB.H. TokP.S.K. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.Emerg. Microbes Infect.20221111343134510.1080/22221751.2022.2072773 35499301
     [Google Scholar]
  6. SuH. ZhouF. HuangZ. Molecular insights into small‐molecule drug discovery for SARS‐CoV‐2.Angew. Chem. Int. Ed.202160189789980210.1002/anie.202008835 32729180
     [Google Scholar]
  7. JacksonC.B. FarzanM. ChenB. ChoeH. Mechanisms of SARS-CoV-2 entry into cells.Nat. Rev. Mol. Cell Biol.202223132010.1038/s41580‑021‑00418‑x 34611326
     [Google Scholar]
  8. KnellerD.W. PhillipsG. O’NeillH.M. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography.Nat. Commun.2020111320210.1038/s41467‑020‑16954‑7 32581217
     [Google Scholar]
  9. KronenbergerT. LauferS.A. PillaiyarT. COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease.Drug Discov. Today202328610357910.1016/j.drudis.2023.103579 37028502
     [Google Scholar]
  10. CuiW. YangK. YangH. Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19.Front. Mol. Biosci.20207761634110.3389/fmolb.2020.616341 33344509
     [Google Scholar]
  11. JinZ. DuX. XuY. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors.Nature2020582781128929310.1038/s41586‑020‑2223‑y 32272481
     [Google Scholar]
  12. PatelCN JaniSP Prasanth KumarS ModiKM KumarY Computational investigation of natural compounds as potential main protease (Mpro) inhibitors for SARS-CoV-2 virus.Comput Biol Med2022151Pt A10631810.1016/j.compbiomed.2022.106318 36423529
     [Google Scholar]
  13. DaiW. ZhangB. JiangX.M. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.Science202036864971331133510.1126/science.abb4489 32321856
     [Google Scholar]
  14. KumarA. ChoudhirG. ShuklaS.K. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches.J. Biomol. Struct. Dyn.202139103760377010.1080/07391102.2020.1772112 32448034
     [Google Scholar]
  15. PandeyP. RaneJ.S. ChatterjeeA. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: An in silico study for drug development.J. Biomol. Struct. Dyn.202139166306631610.1080/07391102.2020.1796811 32698689
     [Google Scholar]
  16. LokwaniD. AzadR. SarkateA. ReddannaP. ShindeD. Structure Based Library Design (SBLD) for new 1,4-dihydropyrimidine scaffold as simultaneous COX-1/COX-2 and 5-LOX inhibitors.Bioorg. Med. Chem.201523154533454310.1016/j.bmc.2015.06.008 26122769
     [Google Scholar]
  17. RaniI. KalsiA. KaurG. Modern drug discovery applications for the identification of novel candidates for COVID-19 infections.Ann. Med. Surg. (Lond.)20228010412510.1016/j.amsu.2022.104125 35845863
     [Google Scholar]
  18. DasA.P. AgarwalS.M. Recent advances in the area of plant-based anti-cancer drug discovery using computational approaches.Mol. Divers.202428290192510.1007/s11030‑022‑10590‑7 36670282
     [Google Scholar]
  19. KoesD.R. BaumgartnerM.P. CamachoC.J. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise.J. Chem. Inf. Model.20135381893190410.1021/ci300604z 23379370
     [Google Scholar]
  20. TiwariS.V. SarkateA.P. LokwaniD.K. Explorations of novel pyridine-pyrimidine hybrid phosphonate derivatives as aurora kinase inhibitors.Bioorg. Med. Chem. Lett.20226712874710.1016/j.bmcl.2022.128747 35476959
     [Google Scholar]
  21. ThoratN.M. KhodadeV.S. IngaleA.P. LokwaniD.K. SarkateA.P. ThopateS.R. Molecular docking studies and application of 6-(1-Arylmethanamino)-2-Phenyl-4 H -Chromen-4-ones as potent antibacterial agents.Polycycl. Aromat. Compd.202343108653866610.1080/10406638.2022.2150238
     [Google Scholar]
  22. KardileR.A. SarkateA.P. LokwaniD.K. TiwariS.V. AzadR. ThopateS.R. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.Eur. J. Med. Chem.2023245Pt 111488910.1016/j.ejmech.2022.114889 36375337
     [Google Scholar]
  23. MohiteP. LokwaniD.K. SakleN.S. Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: Integrating in silico and in vitro investigations.Naunyn Schmiedebergs Arch. Pharmacol.202439786107611910.1007/s00210‑024‑03021‑x 38416196
     [Google Scholar]
  24. YangM. BoZ. XuT. XuB. WangD. ZhengH. Uni-GBSA: An open-source and web-based automatic workflow to perform MM/GB(PB)SA calculations for virtual screening.Brief. Bioinform.2023244bbad21810.1093/bib/bbad218 37328705
     [Google Scholar]
  25. Sousa da SilvaA.W. VrankenW.F. ACPYPE - AnteChamber PYthon Parser interfacE.BMC Res. Notes20125136710.1186/1756‑0500‑5‑367 22824207
     [Google Scholar]
  26. Valdés-TresancoM.S. Valdés-TresancoM.E. ValienteP.A. MorenoE. gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS.J. Chem. Theory Comput.202117106281629110.1021/acs.jctc.1c00645 34586825
     [Google Scholar]
  27. LokwaniD.K. ChavanS.R. SarkateA.P. NatarajanP.M. UmapathyV.R. JainS.P. Virtual screening of natural compounds as potential SARS-CoV-2 main protease inhibitors: A Molecular docking and molecular dynamics simulation guided approach.Chem Proc2023148510.3390/ecsoc‑27‑16049
     [Google Scholar]
  28. LokwaniD. ShahR. MokaleS. ShastryP. ShindeD. Development of energetic pharmacophore for the designing of 1,2,3,4-tetrahydropyrimidine derivatives as selective cyclooxygenase-2 inhibitors.J. Comput. Aided Mol. Des.201226326727710.1007/s10822‑011‑9540‑z 22218727
     [Google Scholar]
  29. ZavodszkyM.I. Stumpff-KaneA.W. LeeD.J. FeigM. Scoring confidence index: Statistical evaluation of ligand binding mode predictions.J. Comput. Aided Mol. Des.200923528929910.1007/s10822‑008‑9258‑8 19153808
     [Google Scholar]
  30. DankwaB. BroniE. EnninfulK.S. KwofieS.K. WilsonM.D. Consensus docking and MM-PBSA computations identify putative furin protease inhibitors for developing potential therapeutics against COVID-19.Struct. Chem.20223362221224110.1007/s11224‑022‑02056‑1 36118173
     [Google Scholar]
  31. FerreiraJ.C. FadlS. VillanuevaA.J. RabehW.M. Catalytic dyad residues His41 and Cys145 impact the catalytic activity and overall conformational fold of the main SARS-CoV-2 protease 3-Chymotrypsin-like protease.Front Chem.20219969216810.3389/fchem.2021.692168 34249864
     [Google Scholar]
  32. MaityD. PalD. MD DaVis: Interactive data visualization of protein molecular dynamics.Bioinformatics202238123299330110.1093/bioinformatics/btac314 35532115
     [Google Scholar]
/content/journals/raaidd/10.2174/0127724344379865250709163918
Loading
Computational Investigation of Natural Substances as SARS-CoV-2 Main Protease Inhibitors: A Virtual Screening Method
Recent Adv Antiinfect Drug Discov 21, 44 (2026); https://doi.org/10.2174/0127724344379865250709163918
/content/journals/raaidd/10.2174/0127724344379865250709163918
/content/journals/raaidd/10.2174/0127724344379865250709163918
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): COVID-19; MD simulations; MM-GBSA; molecular docking; Mpro inhibitor; ZINC database

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test